Biomarkers of Calcific Aortic Valve Disease.
Biomarkers of Calcific Aortic Valve Disease.
复制标题
DOI：
10.1161/atvbaha.116.308615
复制
发表时间：
2017-04
期刊：
影响因子：
--
通讯作者：
Rader DJ
中科院分区：
文献类型：
--
作者：
Small A;Kiss D;Giri J;Anwaruddin S;Siddiqi H;Guerraty M;Chirinos JA;Ferrari G;Rader DJ
钙化性主动脉瓣疾病 (CAVD) 是一种非常普遍的心血管疾病，导致老龄化人口的经济和社会负担不断增加。尽管对疾病的病理生理学进行了持续研究，但仍然没有药物疗法可以预防 CAVD 的进展。生物标志物的发现代表了对 CAVD 风险分层和干预时机的潜在补充方法，并且具有深入了解该疾病的因果因素的优点。生物标志物在动脉粥样硬化性心血管疾病中已得到广泛研究，并成功作为临床和科学目的的添加剂。 CAVD 中的类似研究不太稳健，然而，CAVD 中生物标志物的现有研究表明有望增强临床决策和识别该疾病的致病因素。这篇全面的综述总结了 CAVD 中现有的和新型的生物标志物、它们对理解病理生理学的贡献、潜在的临床实用性，并为指导该领域的未来研究提供了纲要。
Calcific Aortic Valve Disease (CAVD) is a highly prevalent cardiovascular disorder accounting for a rising economic and social burden on aging populations. In spite of continuing study on the pathophysiology of disease, there remain no medical therapies to prevent the progression of CAVD. The discovery of biomarkers represents a potentially complementary approach in stratifying risk and timing of intervention in CAVD, and has the advantage of providing insight into causal factors for the disease. Biomarkers have been studied extensively in atherosclerotic cardiovascular disease, with success as additive for clinical and scientific purposes. Similar research in CAVD is less robust, however, the available studies of biomarkers in CAVD show promise for enhanced clinical decision-making and identification of causal factors for the disease. This comprehensive review summarizes available established and novel biomarkers in CAVD, their contributions toward an understanding of pathophysiology, their potential clinical utility, and provides an outline to direct future research in the field.